Purpose: Recent concerns regarding the clinical utilization of clustered regularly interspaced short palindromic repeats (CRISPR) involve uncertainties about the potential detrimental effects that many arise due to unintended genetic changes, as in off-target mutagenesis, during CRISPR genome surgery. This review gives an overview of offtargeting detection methods and CRISPR's place in the clinical setting, specifically in the field of ophthalmology.
Purpose: Recent concerns regarding the clinical utilization of clustered regularly interspaced short palindromic repeats (CRISPR) involve uncertainties about the potential detrimental effects that many arise due to unintended genetic changes, as in off-target mutagenesis, during CRISPR genome surgery. This review gives an overview of offtargeting detection methods and CRISPR's place in the clinical setting, specifically in the field of ophthalmology.
Results: As CRISPR utilization in the laboratory setting has increased, knowledge regarding CRISPR mechanisms including its off-target effects has also increased. Although a perfect method for achieving 100% specificity is yet to be determined, the past few years have seen many developments in off-targeting detection and in increasing efficacy of CRISPR tools.
Conclusion: The CRISPR system has high potential to be an invaluable therapeutic tool as it has the ability to modify and repair pathogenic retinal lesions. Although it is not yet a perfect system, with further efforts to improve its specificity and efficacy along with careful screening of off-target mutations, CRISPR-mediated genome surgery potential can become maximized and applied to patients.
RETINA 38:1443-1455, 2018 N umerous recent studies have pointed toward both potential promises and perils of clustered regularly interspaced short palindromic repeats (CRISPR) genome surgery in the clinical setting. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Of the potential perils of the CRISPR genome surgery system, one study raised questions about using CRISPR in the clinical setting without further study of offtarget effects. 1, 11 Although this report raises warranted concern, it should also be considered that while the study was in vivo, the CRISPR genome surgery was performed on zygotes, not adult retinae. 11 As such, the off-target effects reported 1 may not necessarily be reflective of therapeutic interventions that may typically occur in postnatal or postmitotic retinas. Interestingly, the heated debate regarding off-target effects was raised when nine clinical trials using CRISPR to treat various malignancies had already begun (Table  1) . Of note, the first patient recruitment for a CRISPR clinical trial occurred in the past year in October 2016 (NCT027933856). This debate and public concern raise the question of whether these clinical trials began too early without proper consideration of safety. 1 Yet, although the debate is a necessary and important consideration, it is also worth noting that all the CRISPR clinical trials that had begun were in Phase I or Phase II, evaluating safety (Table 1) .
It is also important to note that off-targeting effects, unintended mutations that arise from CRISPR engineering, are not new to the world of genetics, and methods for detecting such changes do exist and are in further development. [12] [13] [14] [15] Unintended changes due to DNA engineering in ophthalmology have certainly been encountered before. In 2008, Kleinman et al 16 presented that although choroidal neovascularization could be inhibited by small interfering RNAs (siRNAs), the siRNAs may elicit immune effects as the mechanism of action was in suppressing toll-like receptor 3 (TLR3). This review seeks to address the questions raised by many on the efficacy of CRISPR, safety considerations, and its place in the clinical setting. This review in particular focuses in part on CRISPR-mediated ophthalmic genome surgery.
Brief CRISPR Mechanism
The CRISPR system is a genome engineering tool derived from bacteria and archaea immune systems [17] [18] [19] considered to be highly specific. 7, 17 The CRISPR system has been adapted to serve many purposes in genome engineering including DNA modification and repair, transcription modification, and directed evolution. 7, 8, [20] [21] [22] [23] Such diverse applications of CRISPR have allowed for further study and understanding of CRISPR. As such, much is known about CRISPR and how it can be directed to specific DNA strands. 15, 17, 24 The most commonly used version of CRISPR is comprised of single-guide RNA (sgRNA), 19 denoting a chimera of CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), and CRISPRassociated protein Cas9 endonuclease. 7, 17, 19 The sgRNA binds to the Cas9 which activates the endonuclease. 24 In the actual target DNA, another component is necessary for Cas9 to recognize and cleave at the target location: a protospacer adjacent motif (PAM) adjacent to the target site. [24] [25] [26] The required PAM sequence for spCas9, the most commonly used Cas9 orthologue derived from Streptococcus pyogenes, 3 is "NGG," with N denoting any of the four nucleotides. Once Cas9 makes a double-strand break (DSB) at the target location, the DSB can be repaired in a variety of ways which determines the application of CRISPR; homology-directed repair (HDR) uses a template strand 25, 27 which results in DNA repair of a pathogenic allele to wild-type (WT), and nonhomologous end joining (NHEJ) without a template strand introduces insertions and deletions (INDELs) that results in gene knockout of pathogenic allele by frameshift caused by the nonspecific INDELs. 7, 8, 17, 20 Figure 1 provides a simplified visual schematic.
Along with the development of different CRISPR techniques, studies have also shown that during CRISPR/Cas9-mediated genome engineering, changes to the DNA can also occur at unintended locations, as in off-target sites. 15, [28] [29] [30] [31] [32] This type of off-targeting may arise due to a variety of reasons. One such reason may be that although the lack of the presence of a PAM sequence can become a limiting factor in targeting specific sequences in some cases, the opposite case in which the presence of a PAM sequence in unintended locations may also become targeted by Cas9 seems possible. Another possibility is the fact that Cas9 is directed by RNA, 33 and inside the eukaryotic cell, many noncoding RNAs (ncRNAs) are present playing regulatory roles 34 ; it is possible that these ncRNAs may direct Cas9 to unintended sites. Thus, many efforts to characterize and predict off-target effects of CRISPR exist. 5, 6, 9, 15, 35 The ultimate goal of these studies is to not only identify off-targeting but also determine how CRISPR's specificity can be maximized with minimal off-target effects. 5, 9, 15 Brief Overview of Current Off-Targeting Detection Methods
In recent years, many methods of genome engineering off-targeting detection have been developed. A brief overview of different methods follows. Figure 2 provides a simplified visual overview. A number of reviews are recommended for a more comprehensive overview. 5, 15, [36] [37] [38] Although diverse variations of offtargeting detection methods exist, they can be summarized into the following categories: in silico algorithm predictions, in vitro selection, and genome-wide assays.
A common method used when selecting an sgRNA and checking for off-target mutagenesis is algorithmbased prediction of potential cleavage sites. 9, 13, 31, 39 The algorithms predict off-target cleavage based on sequence similarity to the on-target site. When using in silico prediction methods, the predicted sites are checked for INDELs that may have arisen from NHEJ or nucleic acid bulges that occur due to mismatch or gaps in DNA and sgRNA base pairing. 31, 32 Studies of off-targeting using in silico prediction have revealed many aspects of off-targeting. Mismatched sites can have high-frequency mutagenesis with five or fewer mismatches. 31, 39 It seems that proximal portions (10 to 12 base pairs) to the 59 of the PAM is more determinate of Cas9 specificity than more distal portions. 39 Interestingly, although the PAM sequence is a required component for cleavage, when tested for spCas9 cleavage of sequences with a 59-NAG-39 PAM sequence, cleavage was still achieved at 20% efficiency of that of 59-NGG-39 PAM sequence. 39 In consideration of the current knowledge, in silico prediction methods have shown that the sequence of the sgRNA is perhaps most indicative of mismatches and off-targeting. 9, 13 Current knowledge has allowed for further development in prediction algorithms including online tools such as CRISPR Design Tool, 39 E-CRISP, 40 and Cas-OFFinder. 13 But, perhaps the biggest consideration of in silico prediction methods is that by nature, it is a biased review of off-target sites as the method is based on checking for what is predicted, but not for novel or random potential offtargeting sites that are not yet understood. 38 Another method of detecting off-target mutagenesis is in vitro selection combined with high-throughput sequencing; this method was developed to more comprehensively characterize spCas9 specificity. 30, 41 This method by Pattanayak et al 30 uses partially randomized concatemeric DNA libraries created by rolling-circle amplification of potential cleavage sites. The libraries are cleaved by CRISPR/Cas9, ligationtagged, amplified using PCR, and then analyzed using high-throughput sequencing computational analysis. Pattanayak et al reported this method as a comprehensive method; because each selection library includes 10 12 target sequence variants, it is theoretically large enough to have 10-fold coverage of all sequences with 8 or fewer mutations relative to the target sequence. Pattanayak et al were able to generate over 10 12 potential off-target sites for the target sequences tested, CRISPR GENOME SURGERY AND OFF-TARGETING CHO ET AL better defining cleavage characteristics. However, because the randomized oligonucleotide libraries are created to resemble the target sequence, in vitro selection may still be a biased method of defining off-target sites. 15 To have a true comprehensive understanding of CRISPR/Cas9 actions, especially in off-target sites, an unbiased method is necessary. A number of genomewide assay methods have thus been developed. 15, 36, 38 For a truly unbiased method, whole-genome sequencing (WGS) could identify even single-nucleotide polymorphisms and small INDELs. 42 However, WGS is costly and time-consuming. 36 Another concern with WGS is that although the screening would be accurate for single-cell clones, 42 mosaicism is seen in experimental studies of in vivo CRISPR/Cas9 editing. 11, 43, 44 It would not be feasible to definitively use WGS on every cell in mosaics, but that would be required to truly comprehensively identify off-targeting. 45 Thus, even WGS is still an insensitive method of detecting off-target cleavage. Some groups have adopted using whole-exome sequencing as a more cost-efficient alternative 46 while still detecting changes in the protein-coding regions. 47 However, whole-exome sequencing does not detect changes in introns or regulatory regions and is an even more insensitive measure than WGS. 36 Other methods of genome-wide analyses such as integrase-defective lentiviral vector (IDLV) capture, genome-wide unbiased identification of DSBs enabled by sequencing (GUIDE-seq), high-throughput genome-wide translocation sequencing, breaks labeling, enrichment on streptavidin, and next-generation sequencing (BLESS), and digested genome sequencing (Digenome-seq) have been developed in recent years to meet the need for better offtarget mutagenesis detection. 35, [48] [49] [50] [51] Of these, methods that can capture off-target events in living cells is of particular interest as therapeutic applications of genome engineering will need to be applied to living cells. Gabriel et al 48 developed IDLV capture to show in vivo action of endonucleases by capturing transient DSBs. Integrase-defective lentiviral vector capture is a method that detects for DSBs in the genome by essentially tagging DSBs with IDLV that become integrated, or captured, during NHEJ. The sites of integration are amplified using linear amplification-mediated PCR, and then mapped using high-throughput sequencing. A limitation of IDLV capture, however, is that IDLVs sometimes randomly integrate into the DNA without endonuclease action. Thus, although sites of high-frequency integration can be better identified, and the sites of IDLV capture are not biased by preselection, IDLV capture could show nonspecific events. GUIDE-seq, developed by Tsai et al, 35 is a similar method to IDLV capture but integrates double-stranded oligodeoxynucleotide (dsODN) by NHEJ. Another difference is that GUIDE-seq uses single-tail adapter/tag (STAT)-PCR, which amplifies only the sequences with integrated dsODN, which allows for correction of background and PCR bias. Although GUIDE-seq has high sensitivity with detection of sites with frequencies as low as 0.1% in offtarget DSBs in living cells, the detection relies on dsODN insertion, which may not always occur efficiently and is limited by sequencing reads. Another off-targeting detection tool that can be used in living cells is high-throughput genome-wide translocation sequencing, a modified linear amplification-mediated PCR method by Frock et al. 49 High-throughput genome-wide translocation sequencing uses the detection of translocation events between DSBs created by the endonuclease and off-target DSBs to identify offtarget mutagenesis and chromosomal damage. 49, 52, 53 High-throughput genome-wide translocation sequencing does not require any components other than the CRISPR/Cas9 and sgRNA and therefore has the advantage of not introducing other foreign material. 49 However, the rate at which translocations occur is low and are biased toward cleavage sites that are closer in proximity.
Other genome-wide methods cannot be completed in living cells, but offer other advantages. Crosetto et al 50 developed BLESS, which detects telomere ends and endonuclease-induced DSBs for visualization of a genome-wide DSB landscape. BLESS is able to capture transient DSBs by in situ labeling of DSBs by ligation of biotinylated linkers. Although BLESS is able to detect DSBs after CRISPR/Cas9 delivery in vivo and is a high-resolution method, BLESS requires cell fixation and lysis for analysis. Another approach developed by Kim et al 51 specifically for human cells, Digenome-seq, is an in vitro approach. Digenome-seq is performed by isolating and then digesting the genome in vitro using Cas9 ribonucleoprotein, preassembled Cas9 protein, and sgRNA. The digested genome is analyzed by WGS. In vitro delivery allows the DSB events to be isolated from other in vivo factors such as cell conditions and chromatin accessibility. The preassembled Cas9 ribonucleoprotein also allows for maximization of cleavage events identifying off-target sites with frequency of 0.1% or lower. Other than it being an in vitro approach, Digenome-seq is also limited by WGS background information, as well as potential inefficient sequencing.
Some Characteristics of Off-Targeting
As described above, no current method of off-target detection is completely sensitive or specific, and more developments are needed. Still, despite limitations of off-targeting detection methods, the development of these methods has given a better understanding of Cas9-induced DSBs and off-targeting events. A finding of greatest concern is that some off-target mutagenesis occurs at frequencies equivalent to or higher than the target site, 31, 35 which further emphasizes the need to better define off-targeting. Current understanding of how the CRISPR/Cas9 system determines DSB locations has led to studies focusing on sgRNA's effects on off-targeting. 5, 9 O'Geen et al 9 Fig. 2 . Simplified overview of off-target detection methods. A. In silico algorithm prediction. Computer algorithms are used to predict off-target cleavage sites based on sequence similarities. The predicted sites are checked for off-target cleavage that may have occurred but does not allow for detection of novel or random off-target sites. B. In vitro selection. Partially randomized concatemeric DNA libraries are created through rolling-circle amplification of potential cleavage sites, which are checked for off-target cleavage. Although a large library is created, the sequences are selected for by sequence similarities and may miss some off-target sites. (C) Genome-wide assay. High-throughput sequencing of the entire genome is performed, essentially being an unbiased method as the entire genome is checked for off-target cleavage, although mosaicism may be missed.
report based on a review of in silico predictions, in vitro screenings, and genome-wide detections that what determines CRISPR/Cas9 specificity most is the sgRNA and suggest that it is not Cas9 that should be categorized as specific or nonspecific but rather the sgRNA. Although efforts toward better defining sgRNA sequence for higher specificity exist, further study is needed. 54, 55 About the targeted genome, some studies have shown a correlation between off-targeting and chromatin accessibility and nonmethylated regions. 56, 57 Another characteristic that has been observed by genome-wide assays is up to six mismatches in the PAM and noncanonical PAM sequences seem to be tolerated by Cas9. 15 It has also been shown that Cas9 will cleave DNA sequences in the presence of DNA or RNA bulges created by mismatched target DNA and sgRNA. 32 
CRISPR as a Therapeutic and Safety Considerations
In light of current understanding of off-target mutagenesis, safety considerations for CRISPR/Cas9 as a therapeutic tool are critical. The study by Wu et al 11 "CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinits Pigmentosa" is a relevant and important preclinical model of CRISPR utilization for therapeutic purposes. Wu et al's success in disease model rescue after CRISPR-mediated correction of a pathogenic point mutation is an example of CRISPR's potency as a clinical tool. In recent years, CRISPR has been applied to many different species and to a variety of diseases 5, 58 and the successful applications of CRISPR in disease model rescue has built much anticipation for the benefits of CRISPR. 7, 17 Furthering the anticipation is Ma et al's 59 recent report in August 2017 of CRISPR/Cas9-mediated correction of MYPC3 in human preimplantation embryos. Yet, some respond that correction as described by Ma et al to be unlikely, but rather what likely occurred is deletion of the gene of interest, 60 which raises uncertainty and consideration of safety. In evaluating CRISPR as a therapeutic tool, this review focuses on the retina as the experiment by Wu et al is a retinal disease study, as the vast volume of recent CRISPR-mediated genome engineering does not allow for a comprehensive overview.
The retina is of particular importance as one of the most feared illnesses in America is blindness. 61 This is unsurprising because blindness or low vision can cause impairment in mobility and activities of daily living, and has been linked to depression and anxiety. 61 Retinal pigment epithelium (RPE) disorders, which affect more than 10 million Americans, 62 lead to retinal degenerations causing irreversible blindness, as the RPE has little regenerative potential. 63 At this time, retinal degenerations with genetic cause have no curative treatments available. It is hoped that these previously unapproachable genetic retinal dystrophies may be treated by gene and cell-based therapies. 63 An example of such an approach currently undergoing clinical trials is gene therapy. Gene therapy uses viral vectors to insert therapeutic (or WT) genes 64 ; clinical trials of this therapeutic model have had varying degrees of success. 63, [65] [66] [67] [68] [69] [70] [71] [72] The variability of success has been theorized to be attributable in part to the timing of gene therapy; beyond a certain degree of disease progression, there may be a "point of no return" due to cell death. 65 Another great limitation of gene therapy is its inability to treat dominant mutations; only recessive conditions and haploinsufficiency can be approached through gene therapy because it is a gene addition method. 63 Thus, a different treatment approach is needed. Figure 3 demonstrates this need. The therapeutic method that is expected to have the most potential for success in treating inherited disorders at this time is the CRISPR system. 8, 63, 73 In the laboratory setting, CRISPR/Cas9 has proven to be a useful genome engineering tool in preclinical models, especially in ophthalmology (Tables 2 and 3 ). The advantage of CRISPR is that it has the potential to directly correct the genetic defect in induced pluripotent stem cells (iPSCs), 74 which allows corrections for both dominant and recessive genetic mutations. These corrected iPSCs could be transplanted into the patient's eye as a cell-based therapy potentially curing blindness. 63, 75 In 2015, Bassuk et al 74 were the first to report correction of a retinal dystrophy causative point mutation in patient-derived iPSCs using CRISPR/ Cas9. Since then, a number of groups have reported successful correction of pathogenic mutations in patient-derived iPSCs (Table 3) .
Of the numerous CRISPR system applications, Leber congenital amaurosis (LCA) is of particular interest to the current discussion of CRISPR as a therapeutic in the retina, as Editas and Allergan announced in March 2017 plans to develop CRISPR-mediated treatment of LCA10 and begin testing the treatment in 2018. Leber congenital amaurosis is also important to the discussion of CRISPR correction in general as affected individuals show symptoms within a few months from birth, and the disease-causative mutations are genetically heterogeneous. 76, 77 Of these, LCA10 is caused by the most frequently detected change among the affected individuals: an intronic mutation in CEP290 (c.2991 +1655A.G). CEP290 is challenging to target with CRISPR due to its size exceeding adeno-associated virus (AAV) delivery capacity. 78, 79 A dual AAV approach of pAAV-SpCas9 and pAAV-sgRNA has been shown to circumvent the AAV carrying capacity limitation. 78 Another approach which used a smaller Staphylococcus aureus-derived Cas9 with two guide RNAs has also been shown to be effective in circumventing the AAV carrying capacity limitation. 79 These successful corrections are demonstrative of the accelerated developments for potential application that the field has seen in recent years.
Furthermore, expectations for advances in CRISPR applications in ophthalmology is greater than in other fields as the human retina is one of the simplest areas to evaluate experimental gene and cell therapies because of its relative immune privilege by the blood-retina barrier and easy accessibility for monitoring without invasive techniques. 80 That is to say, one of the safest platforms for evaluating CRISPR's safety in clinical trials may be the eye.
Even still, as discussed above, CRISPR is yet to be developed into a perfect system and there are many considerations especially for clinicians to navigate, including lack of accurate and specific off-target mutagenesis detection tools. 15 When safety is not properly assessed, even in a more ideal platform such as the eye, adverse events can occur. Related to the use of CRISPR is the use of stem cells as a therapeutic as mentioned above. Unfortunately, public perception of stem cells, driven in part by deceptive advertising, has led patients to seek stem cell therapy under unregulated conditions leading to deleterious effects. 81 In such a case, a patient with an inherited retinal dystrophy who was expected to maintain useful vision for many years sought unregulated stem cell treatment and returned with sudden central vision loss in the treated eye. 82 In addition, a recent article "Immunity to CRISPR Cas9 and Cas12a therapeutics" highlights the potential of the CRISPR system to mount a host immune response, through innate, cellular, and humoral immunity. 2 Furthermore, it is noted that CRISPR correction that introduces new protein products, although therapeutic for the treated disease, may introduce immunologically foreign proteins to the host. 2 Thus, in applying CRISPR to patient-derived iPSCs for autologous transplantation, and all other applications of CRISPR as a therapeutic, all the benefits and risks must be considered. Without careful consideration of treatments and all their effects, clinicians may cause more harm than good. For such reasons, efforts to improve CRISPR efficacy, reduce offtargeting, and better understand CRISPR mechanism and its effects are in progress.
Safer CRISPR?
A brief overview of experimental methods of increasing CRISPR/Cas9 specificity is given. For a more complete mechanism of individual methods, studies which report the use of these methods are recommended. 4, 29, [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] As discussed above, the specificity of Cas9 is dependent on the sgRNA sequence. Thus, some methods to improve Cas9 specificity use the sgRNA sequence. 54 One such example is truncated gRNA (tru-gRNA), which is 2 to 3 nucleotides shorter than traditional sgRNAs. 83, 94 Tru-gRNA has been shown to reduce off-target mutagenesis in comparison with traditional sgRNA by 2 to 5-fold, but does not reduce off-target mutagenesis to undetectable levels. 35 Another method uses the opposite approach and elongates the sgRNA using two additional guanine nucleotides to the 59 end. 29 Although the extended gRNA has been shown to reduce off-targeting, it has also been shown to reduce actual on-target site activity as well. Thus, although these two methods of sgRNA manipulation seem to have some success, these methods alone do not seem to be enough for the specificity desired.
In addition, some groups have modified the Cas9 protein itself to improve CRISPR/Cas9 specificity. One method uses paired Cas9 nickases (Cas9n), which create single-strand breaks instead of DSBs. 84, 85 This is achieved by deactivating one of the two nuclease domains of the Cas9. Two separate offset nicks, or single-strand breaks, are made on each strand of DNA, guided by two different sgRNAs. This method has been shown to reduce off-target mutagenesis by 50 to 1500-fold in human cells. It is not yet clear whether the usage of a second sgRNA may cause off-target mutagenesis at other locations. Cas9n has also been observed to have an increased frequency of point mutations, which are more difficult to detect than INDELs. 15, 87 Another variation of the Cas9 protein is dimeric RNA-guided FokI-dCas9nuclease (RFN), which has been created to reduce the off-target effects of Cas9n's activity as a monomer. [86] [87] [88] The variation is created by fusing catalytically inactive Cas9, or dead Cas9 (dCas9) to dimerization-dependent FokI nuclease domain, 95 meaning two colocalized RFN are necessary for cleavage. This dimerization-dependent activity also allows for extended double-length target sites to be recognized for cleavage. RFN in combination with tru-gRNA, also known as tru-RFNs, has been shown to especially reduce off-target monomer activity. 86 The requirements of the dimerization, however, also limit the target range of the endonuclease.
Another variation or approach is engineered variants of SpCas9. SpCas9 high-fidelity variant 1 (SpCas9-HF1) 4 and enhanced specificity SpCas9 version 1.1 (eSpCas9 1.1) 89 have alanine substitutions at the predicted Cas9 protein residue that makes contact with the target DNA. This method disrupts the nonspecific DNA contact points and diminishes off-target events. SpCas9-HF1 and eSpCas9 1.1 both show target site cleavage activity at rates comparable with SpCas9. More recently, another interesting variation of Cas9 has been reported: an expanded PAM SpCas9 variant (xCas9), engineered by phageassisted continuous evolution. 96 xCas9 is unique in that it recognizes a broader range of PAM sequences including NG, GAA, and GAT. The wider PAM recognition widens the scope of genetic sequences accessible to CRISPR. Current experimental data show that although PAM compatibility is broadened, xCas9 actually yields lower rates of off-target activity with increased specificity. Still, although the engineered variants show great specificity with great reduction in off-target events, some off-targeting is observed.
Other methods of improving Cas9 specificity limit the duration of Cas9 activity to reduce the likelihood of off-target events. These methods include utilization of ribonucleoproteins that have been shown to be degraded within 24 hours versus several days of traditional Cas9 delivery. 90 Inducible mechanisms also exist, including split Cas9, which is induced to dimerize in the presence of rapamycin for activation of enzymatic activity. 91 Another inducible mechanism represses the enzymatic activity of Cas9 by intein insertion. 92 This particular insertion is cleaved in the presence of 4-hydroxytamoxifen (4-HT), inducing Cas9 activity. Even a photoactivatable Cas9 (paCas9) exists. 93 PaCas9 is composed of split Cas9 fragments that are fused to dimerization domains called magnets, which dimerize on blue-light irradiation, activating endonuclease activity. Optogenetic control allows an inducible system that is also reversible. A very recent advancement in limiting Cas9 activity duration is the use of anti-CRISPR protein, AcrIIA4, or anti-CRISPR DNA mimic. 97 AcrIIA4 mimics DNA and binds to Cas9-sgRNA complexes, interfering with PAM recognition. AcrIIA4 could be administered after a specified time to stop Cas9 activity. Overall, reducing the duration of Cas9 activity does reduce off-target events, but still does not yield perfect specificity.
Another CRISPR approach that is in development as an alternative to HDR-dependent repair is the use of base editing. [98] [99] [100] [101] Base editing systems are unique because they substitute nucleotides, unlike endonuclease cleavage systems that make DSBs. A thirdgeneration base editor (BE3), which can permanently convert C:G base pairs to T:A base pairs, was introduced in the past year. 99 The BE3 mechanism is similar to a traditional CRISPR system in that a gRNA targets Cas9 to a specific locus. The difference lies in Cas9 engineering; BE3 uses inactive Cas9 tethered to a cytidine deaminase enzyme. 99, 100, 102, 103 On binding of the engineered Cas9 complex to DNA, a small window of DNA is exposed allowing for any cytidine to be deaminated to uracil. Through a series of steps, the mutated U:G is converted to a T:A. 104 Base editing has been applied to induction of STOP codons (iSTOP), which works by converting codons CAA, CAG, CGA, and TGG into STOP codons, TAA, TAG, and TGA. 105 iSTOP is advantageous because it could potentially treat dominant negative disorders without the need for HDR or NHEJ. Another application of base editing is CRISPR-X, which pairs dCas9 with activation-induced cytidine deaminase, resulting in a diverse library of point mutations. 106 Although base editing methods are promising, there are still drawbacks including: conversion of base pairs to T:A at undesired locations, limitation to the C:G to T:A conversion, and varied efficiency depending on the target. Recently, fourth-generation base editing (BE4) has been unveiled, which increases editing efficiency and specificity. 104 BE4 is a fusion of BE3 and Gam, a bacteriophage Mu protein that binds ends of double-stranded DNA. This fusion seems to reduce INDEL formation leading to greater efficiency and specificity, but is still confined to some of the limitations of BE3, specifically the inability to make edits beyond the C:G to T:A conversion.
Conclusion
In recent years, immense research has been completed to improve genome engineering techniques and better understand the mechanisms and effects of genome engineering. Despite great successes and progress, limitations to genome engineering and our understanding of it exist. These limitations bring safety concerns to the usage of CRISPR-mediated genome surgery in the clinical setting. Yet, the CRISPR system has the potential to cure illnesses previously unapproachable. Further efforts to improve CRISPR/Cas9 specificity and efficacy and better define and understand off-target mutagenesis should be made to maximize the potentials of the CRISPR system and apply to clinical therapeutics. There is still great anticipation and expectation for CRISPR to be used as a therapeutic tool, given that it is with warranted judicious care.
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